SIRT1 and cancer: Indeed, we are lacking even a minimal understanding of how pharmacological manipulations targeting core metabolic checkpoints such as AMPK, mTOR, and SIRT1, might fine-tune the expression of immune checkpoint receptors in cancer cells.